CYTK
Price
$32.30
Change
+$0.22 (+0.69%)
Updated
Jun 6 closing price
Capitalization
3.86B
53 days until earnings call
TRAW
Price
$1.65
Change
+$0.17 (+11.49%)
Updated
Jun 6 closing price
Capitalization
9.18M
Interact to see
Advertisement

CYTK vs TRAW

Header iconCYTK vs TRAW Comparison
Open Charts CYTK vs TRAWBanner chart's image
Cytokinetics
Price$32.30
Change+$0.22 (+0.69%)
Volume$768.26K
Capitalization3.86B
Traws Pharma
Price$1.65
Change+$0.17 (+11.49%)
Volume$493.94K
Capitalization9.18M
CYTK vs TRAW Comparison Chart
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRAW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. TRAW commentary
Jun 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Buy and TRAW is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 08, 2025
Stock price -- (CYTK: $32.30 vs. TRAW: $1.65)
Brand notoriety: CYTK and TRAW are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 35% vs. TRAW: 32%
Market capitalization -- CYTK: $3.86B vs. TRAW: $9.18M
CYTK [@Biotechnology] is valued at $3.86B. TRAW’s [@Biotechnology] market capitalization is $9.18M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileTRAW’s FA Score has 1 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • TRAW’s FA Score: 1 green, 4 red.
According to our system of comparison, TRAW is a better buy in the long-term than CYTK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 4 TA indicator(s) are bullish while TRAW’s TA Score has 3 bullish TA indicator(s).

  • CYTK’s TA Score: 4 bullish, 2 bearish.
  • TRAW’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than TRAW.

Price Growth

CYTK (@Biotechnology) experienced а +4.13% price change this week, while TRAW (@Biotechnology) price change was +16.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

CYTK is expected to report earnings on Jul 31, 2025.

TRAW is expected to report earnings on Mar 31, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($3.86B) has a higher market cap than TRAW($9.18M). CYTK YTD gains are higher at: -31.335 vs. TRAW (-81.419). TRAW has higher annual earnings (EBITDA): -24.08M vs. CYTK (-513.62M). CYTK has more cash in the bank: 938M vs. TRAW (5.41M). CYTK has higher revenues than TRAW: CYTK (19.2M) vs TRAW (226K).
CYTKTRAWCYTK / TRAW
Capitalization3.86B9.18M42,022%
EBITDA-513.62M-24.08M2,133%
Gain YTD-31.335-81.41938%
P/E RatioN/AN/A-
Revenue19.2M226K8,496%
Total Cash938M5.41M17,338%
Total Debt791MN/A-
FUNDAMENTALS RATINGS
CYTK vs TRAW: Fundamental Ratings
CYTK
TRAW
OUTLOOK RATING
1..100
649
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
29
Undervalued
PROFIT vs RISK RATING
1..100
83100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
8665
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TRAW's Valuation (29) in the Biotechnology industry is significantly better than the same rating for CYTK (100). This means that TRAW’s stock grew significantly faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (83) in the Biotechnology industry is in the same range as TRAW (100). This means that CYTK’s stock grew similarly to TRAW’s over the last 12 months.

CYTK's SMR Rating (99) in the Biotechnology industry is in the same range as TRAW (100). This means that CYTK’s stock grew similarly to TRAW’s over the last 12 months.

TRAW's Price Growth Rating (65) in the Biotechnology industry is in the same range as CYTK (86). This means that TRAW’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for TRAW (100). This means that CYTK’s stock grew significantly faster than TRAW’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKTRAW
RSI
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
82%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
78%
Bullish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 10 days ago
76%
Declines
ODDS (%)
Bearish Trend 12 days ago
78%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
86%
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRAW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VMSGX21.620.25
+1.17%
VALIC Company I Mid Cap Strategic Gr
VFFSX294.243.03
+1.04%
Vanguard 500 Index Institutional Select
JFNIX66.370.63
+0.96%
Janus Henderson Global Life Sciences I
WBCIX15.950.15
+0.95%
William Blair Small-Mid Cap Core I
ZGFIX19.800.13
+0.66%
American Beacon Ninety One Gbl Frnchs R5

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with KRYS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
+0.69%
KRYS - CYTK
47%
Loosely correlated
+3.26%
IDYA - CYTK
47%
Loosely correlated
+2.99%
IMVT - CYTK
46%
Loosely correlated
+4.68%
TRDA - CYTK
44%
Loosely correlated
+2.46%
ACLX - CYTK
44%
Loosely correlated
+2.79%
More

TRAW and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRAW has been loosely correlated with SLGL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if TRAW jumps, then SLGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRAW
1D Price
Change %
TRAW100%
+11.49%
SLGL - TRAW
46%
Loosely correlated
+0.07%
RAPT - TRAW
46%
Loosely correlated
+14.71%
MDGL - TRAW
39%
Loosely correlated
+1.51%
CYTK - TRAW
36%
Loosely correlated
+0.69%
ORMP - TRAW
34%
Loosely correlated
+3.26%
More